phytogenic antineoplastic agents

Summary

Summary: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Top Publications

  1. ncbi Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    William J Gradishar
    Northwestern University, Breast Oncology, Division of Hematology Oncology, Department of Medicine, Chicago, IL 60611, USA
    J Clin Oncol 23:7794-803. 2005
  2. ncbi Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies
    Bharat B Aggarwal
    Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Anticancer Res 24:2783-840. 2004
  3. ncbi Disrupting tumour blood vessels
    Gillian M Tozer
    Academic Unit of Surgical Oncology, Division of Clinical Sciences, University of Sheffield, Floor K, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
    Nat Rev Cancer 5:423-35. 2005
  4. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
  5. ncbi UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    L Iyer
    Department of Medicine, The University of Chicago, IL, USA
    Pharmacogenomics J 2:43-7. 2002
  6. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
  7. ncbi Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    Tae You Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 10:3708-16. 2004
  8. pmc Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations
    Giovanni Chillemi
    CASPUR Inter University Consortium for the Application of Super Computing for Universities and Research, Via dei Tizii 6, Rome 00185, Italy
    Nucleic Acids Res 36:5645-51. 2008
  9. ncbi Pharmacogenetics of paclitaxel metabolism
    Jennifer Spratlin
    Cross Cancer Institute, Department of Medical Oncology, University of Alberta, Edmonton, Alberta, Canada
    Crit Rev Oncol Hematol 61:222-9. 2007
  10. ncbi 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
    R S Kerbel
    Sunnybrook and Women s College Health Sciences Centre, Division of Cancer Biology Research, S 218, 2075 Bayview Avenue, Ontario M4N 3M5, Toronto, Canada
    Eur J Cancer 36:1248-57. 2000

Detail Information

Publications331 found, 100 shown here

  1. ncbi Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    William J Gradishar
    Northwestern University, Breast Oncology, Division of Hematology Oncology, Department of Medicine, Chicago, IL 60611, USA
    J Clin Oncol 23:7794-803. 2005
    ..This phase III study was performed to confirm preclinical studies demonstrating superior efficacy and reduced toxicity of ABI-007 compared with standard paclitaxel...
  2. ncbi Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies
    Bharat B Aggarwal
    Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Anticancer Res 24:2783-840. 2004
    ..Limited data in humans have revealed that resveratrol is pharmacologically quite safe. Currently, structural analogues of resveratrol with improved bioavailability are being pursued as potential therapeutic agents for cancer...
  3. ncbi Disrupting tumour blood vessels
    Gillian M Tozer
    Academic Unit of Surgical Oncology, Division of Clinical Sciences, University of Sheffield, Floor K, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
    Nat Rev Cancer 5:423-35. 2005
    ....
  4. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  5. ncbi UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    L Iyer
    Department of Medicine, The University of Chicago, IL, USA
    Pharmacogenomics J 2:43-7. 2002
    ..The results suggest that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity...
  6. ncbi Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    Nasser Hanna
    Indiana University, 535 Barnhill Dr, Room 473, Indianapolis, IN 46202, USA
    J Clin Oncol 22:1589-97. 2004
    ..To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy...
  7. ncbi Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
    Tae You Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 10:3708-16. 2004
    ..A phase I study was performed to determine the maximum tolerated dosage, dose-limiting toxicities, and the pharmacokinetic profile of Genexol-PM in patients with advanced, refractory malignancies...
  8. pmc Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations
    Giovanni Chillemi
    CASPUR Inter University Consortium for the Application of Super Computing for Universities and Research, Via dei Tizii 6, Rome 00185, Italy
    Nucleic Acids Res 36:5645-51. 2008
    ....
  9. ncbi Pharmacogenetics of paclitaxel metabolism
    Jennifer Spratlin
    Cross Cancer Institute, Department of Medical Oncology, University of Alberta, Edmonton, Alberta, Canada
    Crit Rev Oncol Hematol 61:222-9. 2007
    ..Here we review the pharmacology of paclitaxel and consider the possible effects pharmacogenetics may have on paclitaxel therapy...
  10. ncbi 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
    R S Kerbel
    Sunnybrook and Women s College Health Sciences Centre, Division of Cancer Biology Research, S 218, 2075 Bayview Avenue, Ontario M4N 3M5, Toronto, Canada
    Eur J Cancer 36:1248-57. 2000
    ....
  11. ncbi p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition
    Yinglin Wang
    Department of Pathology and Laboratory Medicine, UCLA School of Medicine, 13 317 Center for the Health Science, Los Angeles, CA 90095 1732, USA
    Oncogene 23:1283-90. 2004
    ..These results indicate that p53 disruption has a dramatic effect on how glioblastoma cells process topoisomerase I inhibitor-mediated DNA damage...
  12. ncbi Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase
    Toshiki Tanaka
    Brander Cancer Research Institute, Department of Pathology, New York Medical College, Valhalla, New York 10595, USA
    Cell Cycle 6:371-6. 2007
    ..mitoxantrone, may contribute to formation of DSBs and to triggering of apoptosis...
  13. ncbi Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine
    V K Ngan
    Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, California 93106, USA
    Mol Pharmacol 60:225-32. 2001
    ..3 +/- 0.1 microM), and more than 10-fold lower for vinblastine (130 +/- 7 nM), suggesting that intracellular binding reservoir(s) may be partially responsible for vinflunine's high efficacy and minimal side effects...
  14. ncbi Mechanism of action of camptothecin
    L F Liu
    Department of Pharmacology, UMDNJ Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA
    Ann N Y Acad Sci 922:1-10. 2000
    ..The second involves SUMO conjugation to topo-I. The potentials roles of these new mechanisms for repair of topo-I-mediated DNA damage in determining CPT sensitivity/resistance in tumor cells are discussed...
  15. ncbi Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles
    Lei Yang
    School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang City, Liaoning, China
    Int J Pharm 340:163-72. 2007
    ..These results suggest that the HCPT-BSA nanoparticles seem to be a stable delivery system for poorly soluble HCPT or its derivatives...
  16. ncbi Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
    Y Ando
    First Department of Internal Medicine, Nagoya University School of Medicine, Japan
    Cancer Res 60:6921-6. 2000
    ..This research warrants a prospective trial to corroborate the usefulness of gene diagnosis of UGT1A1 polymorphisms prior tb irinotecan chemotherapy...
  17. ncbi Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris
    Bang Yeon Hwang
    Program for Collaborative Research in the Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    J Org Chem 69:3350-8. 2004
    ..Silvestrol (1) was further evaluated in vivo in the hollow fiber test and in the murine P-388 leukemia model...
  18. ncbi Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse
    M Mahyar-Roemer
    Internal Medicine IV, University of Saarland Medical School, Homburg/Saar, Germany
    Int J Cancer 94:615-22. 2001
    ..Remarkably, apoptosis was preceded by mitochondrial proliferation and signs of epithelial differentiation. Thus, resveratrol triggers a p53-independent apoptotic pathway in HCT116 cells that may be linked to differentiation...
  19. ncbi Pharmacokinetic optimisation of treatment with oral etoposide
    Giuseppe Toffoli
    Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
    Clin Pharmacokinet 43:441-66. 2004
    ..However, they lack precision and accuracy and need to be refined by considering other predictor variables in order to extend their application in current clinical practice...
  20. ncbi Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells
    V M Adhami
    Department of Dermatology, Case Western Reserve University and The Research Institute of University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA
    Biochem Biophys Res Commun 288:579-85. 2001
    ..To our knowledge, this is the first study showing the involvement of the pRb-E2F/DP pathway as a mechanism of the cancer-chemopreventive effects of resveratrol...
  21. ncbi Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)
    I E L M Kuppens
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 55:72-8. 2005
    ..Furthermore, the safety of combined treatment was determined and whether known functional genetic polymorphisms of the MDR1 gene could be associated with variability in docetaxel pharmacokinetics was also investigated...
  22. ncbi Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Mary E R O'Brien
    Royal Marsden Hospital, London, United Kingdom
    J Thorac Oncol 3:728-34. 2008
    ..Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid, may enhance the therapeutic index of paclitaxel...
  23. ncbi Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors
    Sudhakar Chintharlapalli
    Institute of Biosciences and Technology, Texas A and M University Health Science Center, Houston, Texas 77843 4466, USA
    Cancer Res 67:2816-23. 2007
    ..Thus, betulinic acid acts as a novel anticancer agent through targeted degradation of Sp proteins that are highly overexpressed in tumors...
  24. ncbi Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation
    Ramachandra K Reddy
    Department of Biochemistry and Molecular Biology and the USC Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, California 90089 9176, USA
    J Biol Chem 278:20915-24. 2003
    ..Lastly, a GRP78 mutant deleted of its ATP binding domain fails to bind procaspase-7 and loses its protective effect against etoposide-induced apoptosis...
  25. ncbi Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
    S S Bacus
    Quantitative Diagnostic Laboratories, Inc, Elmhurst, Illinois 60126, USA
    Oncogene 20:147-55. 2001
    ..However, p53 may serve as a survival factor in breast carcinoma cells treated with Taxol by blocking cells in G2/M phase of the cell cycle...
  26. ncbi Inhibition of cancer growth by resveratrol is related to its low bioavailability
    Miguel Asensi
    Departamento de Fisiologia, Universidad de Valencia, Valencia, Spain
    Free Radic Biol Med 33:387-98. 2002
    ....
  27. pmc Are isothiocyanates potential anti-cancer drugs?
    Xiang Wu
    Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China
    Acta Pharmacol Sin 30:501-12. 2009
    ..This review summarizes the current knowledge on isothiocyanates and focuses on their role as potential anti-cancer agents...
  28. ncbi UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
    Jean Francois Cote
    Institut National de la Sante et de la Recherche Medicale UMR S775, Bases Moléculaires de la Réponse aux Xénobiotiques, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, France
    Clin Cancer Res 13:3269-75. 2007
    ....
  29. pmc The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1
    G A Potter
    Cancer Drug Discovery Group, School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK
    Br J Cancer 86:774-8. 2002
    ..Importantly this result gives insight into the functional role of CYP1B1 and provides evidence for the concept that CYP1B1 in tumours may be functioning as a growth suppressor enzyme...
  30. ncbi The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons
    Karen Flatten
    Division of Oncology Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 280:14349-55. 2005
    ..Collectively, these results show that the ATR/Chk1 pathway plays a predominant role in the response to topoisomerase I inhibitors in carcinoma cells and identify a potential approach for enhancing the efficacy of these drugs...
  31. ncbi Protein nanoparticles as drug carriers in clinical medicine
    Michael J Hawkins
    Abraxis Bioscience, Inc, Los Angeles, CA 90025, USA
    Adv Drug Deliv Rev 60:876-85. 2008
    ..The nab technology promises to have broad utility in cancer therapy, and clinical trials are underway using nab formulations of other water-insoluble anticancer agents such as docetaxel and rapamycin...
  32. ncbi Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004
    ....
  33. ncbi The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine
    M Fan
    Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205-7199, USA
    Cancer Res 61:4450-8. 2001
    ....
  34. ncbi A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol
    J Gusman
    Laboratoire de Pharmacognosie et Bromatologie CP205 4, Institut de Pharmacie, Universite Libre de Bruxelles, Campus Plaine, Boulevard du Triomphe, 1050 Brussels, Belgium
    Carcinogenesis 22:1111-7. 2001
    ..These include cyclooxygenase, nitric oxide synthase and cytochrome P450 inhibition, as well as cell cycle effects, apoptosis modulation and hormonal activity...
  35. ncbi Methyl jasmonate-induced overproduction of paclitaxel and baccatin III in Taxus cell suspension cultures
    Y Yukimune
    Bioscience Laboratory, Mitsui Petrochemical Industries, Ltd, Yamaguchi, Japan
    Nat Biotechnol 14:1129-32. 1996
    ..These results suggest that these two regions of methyl jasmonate are important for promoting the production of paclitaxel and related taxanes in Taxus cell cultures...
  36. pmc Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells
    Timothy F Burns
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Mol Cell Biol 23:5556-71. 2003
    ..Finally, these studies suggest that disruption of Snk/Plk2 may be of therapeutic value in sensitizing paclitaxel-resistant tumors...
  37. ncbi Resveratrol-induced autophagocytosis in ovarian cancer cells
    Anthony W Opipari
    Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 64:696-703. 2004
    ....
  38. ncbi Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    David W Nyman
    Department of Pharmacology Toxicology, Division of Hematology Oncology, Arizona Cancer Center University of Arizona Health Sciences Center, Tucson, USA
    J Clin Oncol 23:7785-93. 2005
    ..This study determined the maximum-tolerated dose (MTD) of ABI-007 monotherapy administered weekly (three weekly doses, repeated every 4 weeks) and assessed the pharmacokinetics of paclitaxel administered as ABI-007...
  39. pmc Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
    S Ranganathan
    Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 77:562-6. 1998
    ....
  40. ncbi Taxol induces caspase-10-dependent apoptosis
    Soo Jung Park
    Department of Pharmacology and Toxicology and Indiana University Cancer Center, Indianapolis, Indiana 46202, USA
    J Biol Chem 279:51057-67. 2004
    ..Therefore, these results demonstrate for the first time that taxol induces FADD-dependent apoptosis primarily through activation of caspase-10 but independently of death receptors...
  41. ncbi Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials
    Andrew Vickers
    Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 20:1069-79. 2002
    ..Phase I and II methodology is also problematic: botanicals have low toxicity and are unlikely to cause rapid tumor regression. There is currently minimal regulation of botanical medicines...
  42. ncbi The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair
    Jun Hayakawa
    Department of Cancer Gene Therapy, Sidney Kimmel Cancer Center, San Diego, California 92121, USA
    J Biol Chem 278:20582-92. 2003
    ..JNK may be a rational target for sensitizing tumor cells to DNA-damaging chemotherapy agents...
  43. ncbi Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
    ..Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life...
  44. ncbi Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1
    Ling Hua Meng
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 64:9086-92. 2004
    ..Collectively, these results show that tetrandrine arrests cells in G(1) by convergent mechanisms, including down-regulation of E2F1 and up-regulation of p53/p21(Cip1)...
  45. ncbi Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer
    C C Lee
    Department of Pharmacy, King s College London, London SE1 9NN, UK
    J Ethnopharmacol 100:237-43. 2005
    ..59 microM). The Malaysian Alpinia galanga showed weak activity compared with the Thai sample and this was shown to be due to the relatively high amounts of 1'-acetoxychavicol acetate present in the Thai sample...
  46. ncbi A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS
    L Mu
    Division of Bioengineering, The National University of Singapore, 9 Engineering Drive 1, 117576, Singapore, Singapore
    J Control Release 86:33-48. 2003
    ..Nanoparticles of nanometer size with narrow distribution can be obtained. A drug encapsulation efficiency as high as 100% can be achieved and the release kinetics can be controlled...
  47. ncbi Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Charles S Fuchs
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:807-14. 2003
    ..We prospectively compared the efficacy and tolerability of two irinotecan regimens (once a week for 4 weeks followed by a 2-week rest period [weekly] v once every 3 weeks) in such patients...
  48. ncbi Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer
    Elizabeth Alli
    The Cancer Institute of New Jersey, Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, New Jersey 08901, USA
    Cancer Res 62:6864-9. 2002
    ..Mutant p53 breast cancers exhibiting high levels of stathmin may be resistant to antimicrotubule agents...
  49. ncbi Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells
    Nicolas Andre
    UMR 6032, University of La Méditerranée, UFR of Pharmacy, 27 Bd Jean Moulin, 13005 Marseille, France
    FEBS Lett 532:256-60. 2002
    ..Thus, paclitaxel targets mitochondria upstream of caspase activation, early during the apoptotic process in intact human neuroblastoma cells...
  50. ncbi Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules
    Malathi Hari
    Discovery Oncology, Wyeth, 401 North Middletown Road, Room 4709, Building 200, Pearl River, NY 10965, USA
    Mol Cancer Ther 5:270-8. 2006
    ..These results suggest that a mutation in tubulin might affect microtubule stability as well as drug binding and contribute to the observed resistance profile...
  51. ncbi Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9
    Sanjeev Banerjee
    Cytokine Research Laboratory, Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:4945-54. 2002
    ..Overall, our results suggest that resveratrol suppresses DMBA-induced mammary carcinogenesis, which correlates with down-regulation of NF-kappaB, cyclooxygenase-2, and matrix metalloprotease-9 expression...
  52. ncbi Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types
    Jan H Kessler
    Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Cancer Lett 251:132-45. 2007
    ..Our results substantiate the possible application of BA as a chemotherapeutic agent for the most prevalent human cancer types...
  53. pmc Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group
    A Sulkes
    Institute of Oncology, Beilinson Medical Center, Petah Tiqva, Israel
    Br J Cancer 70:380-3. 1994
    ..There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted...
  54. ncbi Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
    J G Slatter
    Pharmacia and Upjohn Company, Kalamazoo, Michigan 49007, USA
    Drug Metab Dispos 28:423-33. 2000
    ..These results show that the parent drug and its three major metabolites account for virtually all CPT-11 disposition, with fecal excretion representing the major elimination pathway...
  55. ncbi Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
    V M Herben
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute, and Department of Pharmacy and Pharmacology, Slotervaart Hospital Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 17:1897-905. 1999
    ..To evaluate the feasibility of administering irinotecan as a continuous intravenous infusion for 14 to 21 days...
  56. ncbi VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
    Yean K Lee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:788-94. 2004
    ..Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death...
  57. ncbi Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target
    Mei Lan He
    Institute of Cancer Research, Life Science and Technology School, Tongji University, Shanghai 200092, China
    Acta Pharmacol Sin 28:446-52. 2007
    ....
  58. ncbi Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia
    K V Balan
    Department of Biology, University of Miami, Coral Gables, Miami, FL, USA
    Phytomedicine 14:263-72. 2007
    ....
  59. ncbi Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    L Zelek
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Cancer 92:2267-72. 2001
    ..The objective of the study was to assess the tolerance and efficiency of weekly vinorelbine in metastatic breast carcinoma after failure with taxanes...
  60. ncbi A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 15:1358-65. 2004
    ..A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer...
  61. ncbi beta-Sitosterol activates Fas signaling in human breast cancer cells
    A B Awad
    Department of Exercise and Nutrition Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA
    Phytomedicine 14:747-54. 2007
    ..These findings support the hypothesis that beta-sitosterol is an effective apoptosis-promoting agent and that incorporation of more phytosterols in the diet may serve a preventive measure for breast cancer...
  62. ncbi A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity
    S Lobert
    School of Nursing, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA
    Mol Pharmacol 53:908-15. 1998
    ..These data are entirely consistent with our hypothesis that vinflunine is likely to result in reduced clinical neurotoxicity relative to vinorelbine, vinblastine, and vincristine...
  63. ncbi Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Federico Innocenti
    Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 22:1382-8. 2004
    ..UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the glucuronidation of the active metabolite SN-38. This study prospectively evaluated the association between the prevalence of severe toxicity and UGT1A1 genetic variation...
  64. ncbi Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells
    Po Lin Kuo
    Graduate Institute of Natural Products, Kaohsiung Medical University, 100 Shih Chuan 1st Road, Taiwan
    Life Sci 73:243-52. 2003
    ..Taken together, p53 and Fas/FasL apoptotic system possibly participated in the antiproliferative activity of tetrandrine in Hep G2 cells...
  65. ncbi Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan
    Ron H J Mathijssen
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, PO Box 5201, Rotterdam, 3008 AE, The Netherlands
    Curr Cancer Drug Targets 2:103-23. 2002
    ....
  66. pmc The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death
    Isabelle Petit
    Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, Department of Genetic Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY 10021, USA
    Blood 111:1951-61. 2008
    ..As such, CA4P provides for an effective means to treat refractory organ-infiltrating leukemias...
  67. ncbi Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression
    L Tessitore
    Dipartimento di Scienze Chimiche Alimentari Farmaceutiche e Farmacologiche, Universita del Piemonte Orientale Amedeo Avogadro, Vercelli, Italy
    Carcinogenesis 21:1619-22. 2000
    ..In conclusion, the results suggest a protective role of RV in colon carcinogenesis with a mechanism involving changes in bax and p21 expression...
  68. ncbi Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion
    Zih Rou Huang
    Pharmaceutics Laboratory, Chang Gung University, Taoyuan, Taiwan, China
    Acta Pharmacol Sin 29:1094-102. 2008
    ..The aim of this study was to develop and characterize lipid nanoparticles with different lipid cores which can circumvent these problems...
  69. ncbi Natural products in anticancer therapy
    A B da Rocha
    Comprehensive Cancer Center, The Lutheran University of Brazil, Canoas, RS
    Curr Opin Pharmacol 1:364-9. 2001
    ..Other agents originating from marine sources are bryostatin-1, aplidine, dolastatin 10 and ET-743, which have recently entered phase I and II clinical trials...
  70. ncbi Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
    S M Galbraith
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood, HA6 2JR
    Anticancer Res 21:93-102. 2001
    ..Differences in the recovery from the shape changes induced by CA4P and colchicine could underlie the different toxicity profiles of these drugs...
  71. ncbi Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918
    M Maliepaard
    Division of Experimental Therapy, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
    Clin Cancer Res 7:935-41. 2001
    ..This observation may have important clinical implications for future development of novel camptothecins...
  72. ncbi Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation
    Syed M Meeran
    Department of Dermatology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294, USA
    Toxicol Appl Pharmacol 229:33-43. 2008
    ....
  73. ncbi Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells
    Hak Jun Ahn
    Department of Anesthesiology and Pain Management, College of Medicine, University of Ulsan, Seoul Asan Medical Center, Seoul, Korea
    J Cell Biochem 91:1043-52. 2004
    ..Taken together, these findings suggest that in SKOV3 cells, taxol induces caspase-independent AIF-dependent apoptosis...
  74. ncbi Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis
    Ming Tan
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Mol Cell 9:993-1004. 2002
    ..Expressing a nonphosphorylatable mutant of Cdc2 renders cells more sensitive to taxol-induced apoptosis. Thus, ErbB2 membrane RTK can confer resistance to taxol-induced apoptosis by directly phosphorylating Cdc2...
  75. ncbi Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations
    A Zhang
    Bio X Center, Shanghai Jiao Tong University, Shanghai, China
    Pharmacogenomics J 7:333-8. 2007
    ..Our results indicate that heterogeneity among different ethnic populations is possibly the result of microevolution and is relevant to studies into the effect of tailored drug treatment...
  76. ncbi Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin
    Zhiyong Han
    Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, USA
    J Biol Chem 277:17154-60. 2002
    ..These observations demonstrated that p21 was required for senescence development of HCT116 cells following treatment with low concentrations of CPT...
  77. ncbi Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
    L B Saltz
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:2959-67. 1996
    ....
  78. ncbi Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group
    P Schoffski
    Department of Hematology Oncology, Hannover University Medical School, Germany
    Ann Oncol 10:119-22. 1999
    ..The EORTC ECSG performed a multicenter phase II study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck to evaluate the antitumor efficacy and toxicity of this combination...
  79. ncbi Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
    Pascal Seve
    Service de Medecine Interne, Hospices Civils de Lyon, France
    Mol Cancer Ther 4:2001-7. 2005
    ....
  80. ncbi Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis
    X H Yang
    Lurie Cancer Center, Northwestern University Medical School, Evanston Northwestern Healthcare, Illinois 60201, USA
    Cancer Res 61:348-54. 2001
    ..Our results also suggest that caspase 3 deficiency may contribute to chemotherapeutic resistance in breast cancer...
  81. ncbi Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release
    Zhiping Zhang
    Department of Chemical and Biomolecular Engineering, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore
    Biomaterials 27:262-70. 2006
    ..The drug release from PLA-TPGS nanoparticles was found to be biphasic with an initial burst of 17% in the first day, followed by a sustained pattern with 51% release after 31 days...
  82. ncbi SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance
    M Barancik
    Institute for Heart Research, Slovak Academy of Sciences, Dubravska cesta 9, 842 33, Bratislava, Slovak Republic
    Eur J Pharm Sci 14:29-36. 2001
    ..However, the mechanisms of SB203580 action should be further investigated...
  83. ncbi Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions
    W S Ahn
    Department of Obstetrics and Gynaecology, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Eur J Cancer Prev 12:383-90. 2003
    ....
  84. pmc Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene
    S Sale
    Department of Oncology, University of Leicester, Leicester, UK
    Br J Cancer 90:736-44. 2004
    ....
  85. ncbi Effects of betulinic acid alone and in combination with irradiation in human melanoma cells
    E Selzer
    Department of Radiotherapy and Radiobiology, University Hospital, Vienna, Austria
    J Invest Dermatol 114:935-40. 2000
    ....
  86. ncbi Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes
    Xiaohua Gao
    Division of Hematology and Oncology, Henry Ford Health System, Detroit, MI 48202, USA
    J Nutr 132:2076-81. 2002
    ..Thus, despite strong antiproliferative and proapoptotic activities of resveratrol against 32Dp210 cells in vitro, a potential antileukemia effect in vivo, if present, occurs only in a small fraction of mice...
  87. pmc The biology of the combretastatins as tumour vascular targeting agents
    Gillian M Tozer
    Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
    Int J Exp Pathol 83:21-38. 2002
    ..This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential...
  88. ncbi AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol
    Shubha Anand
    CR UK Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison MRC Research Centre, University of Cambridge, Hills Road, Cambridge CB2 2XZ, United Kingdom
    Cancer Cell 3:51-62. 2003
    ..Consistent with this conclusion, elevated Aurora-A expression causes resistance to apoptosis induced by Taxol in a human cancer cell line...
  89. ncbi Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells
    Jun Hyuk Lee
    Department of Oriental Medicine, Dongeui University College of Oriental Medicine and Research Institute of Oriental Medicine, Busan 614 052, Korea
    Int J Oncol 21:1239-44. 2002
    ..These results suggest that tetrandrine merits further investigation as a cell cycle blocker as well as a cancer chemopreventive agent...
  90. ncbi Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells
    Hiroaki Kajiyama
    Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
    Int J Oncol 31:277-83. 2007
    ..It is possible that therapeutic benefits such as the restoration of chemosensitivity or suppression of metastasis will be enabled by gaining further insight into the mechanisms underlying chemoresistance and EMT...
  91. pmc Reactive oxygen species involved in trichosanthin-induced apoptosis of human choriocarcinoma cells
    C Zhang
    Molecular and Nano Sciences Laboratory, Department of Physics, Tsinghua University, Beijing 100084, China
    Biochem J 355:653-61. 2001
    ..formation via the Fenton reaction. The finding that ROS is involved in the TCS-induced apoptosis of JAR cells might provide new insight into the anti-tumour and anti-HIV mechanism of TCS...
  92. ncbi Resveratrol-induced apoptotic death in human U251 glioma cells
    Hao Jiang
    William T Gossett Neurology Laboratories, Henry Ford Health System, Detroit, Michigan 48202, USA
    Mol Cancer Ther 4:554-61. 2005
    ..These results suggest that multiple signaling pathways may underlie the apoptotic death of U251 glioma induced by resveratrol, which warrants further exploration as an anticancer agent in human glioma...
  93. pmc Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
    J S Kloover
    Department of Pulmonology, Erasmus MC, Postbus 2040, 3000 CA Rotterdam, The Netherlands
    Br J Cancer 90:304-5. 2004
    ..The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone...
  94. ncbi Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells
    Praveen K Vayalil
    Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Prostate 59:33-42. 2004
    ..Therefore, the effect of (-)-epigallocatechin-3-gallate (EGCG) was determined on the synthesis and activation of tumor invasion-specific MMP-2 and MMP-9 in human prostate carcinoma DU-145 cells...
  95. ncbi Anticancer activity of isoobtusilactone A from Cinnamomum kotoense: involvement of apoptosis, cell-cycle dysregulation, mitochondria regulation, and reactive oxygen species
    Chung Yi Chen
    School of Medicine and Health Sciences, Fooyin University, Kaohsiung County 831, Taiwan, Republic of China
    J Nat Prod 71:933-40. 2008
    ..Finally, we found that IOA inhibited the migration and invasion of A549 cell migration and invasion. Taken together, these results suggest that IOA has anticancer effects on A549 cells...
  96. ncbi Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel
    Ian C Smith
    Department of Academic Radiology, University of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
    J Clin Oncol 20:1456-66. 2002
    ..To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT)...
  97. ncbi Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein
    Yun Jin Jung
    Cell and Cancer Biology Branch, Center for Cancer Research, NCI, National Institutes of Health, Rockville, Maryland 20850, USA
    J Biol Chem 278:7445-52. 2003
    ..Collectively, these data support a model in which NFkappaB is a focal point for the convergence of MDA-mediated signaling events leading to HIF-1 induction, thus revealing a novel aspect of HIF-1alpha regulation and function...
  98. ncbi Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
    Vernon Harvey
    Department of Oncology, Auckland Hospital, Private Bag 92 024, Auckland, New Zealand
    J Clin Oncol 24:4963-70. 2006
    ..To evaluate whether a relationship exists between docetaxel dose and clinical response in the treatment of patients with advanced breast cancer...
  99. ncbi Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana
    Bolleddula Jayaprakasam
    Bioactive Natural Products and Phytoceuticals, Department of Horticulture, Michigan State University, East Lansing, MI 48824, USA
    Cancer Lett 189:11-6. 2003
    ..Vioxx showed specific COX-2 inhibition by 71%. Also, cucurbitacins 1 and 4 inhibited lipid peroxidation by 59 and 23%, respectively, at 100 microg/ml...
  100. ncbi Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage
    Noritaka Adachi
    Kihara Institute for Biological Research, Graduate School of Integrated Science, Yokohama City University, Totsuka ku, Yokohama 244 0813, Japan
    J Biol Chem 278:35897-902. 2003
    ..The outstandingly increased cytotoxicity of topo II inhibitors in the absence of NHEJ suggests that simultaneous inhibition of topo II and NHEJ would provide a powerful protocol in cancer chemotherapy involving topo II inhibitors...
  101. ncbi Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
    M R Redinbo
    Biomolecular Structure Center and Department of Biological Structure, Box 357742, School of Medicine, University of Washington, Seattle, WA 98195, USA
    Science 279:1504-13. 1998
    ..A binding mode for the anticancer drug camptothecin is proposed on the basis of chemical and biochemical information combined with these three-dimensional structures of topoisomerase I-DNA complexes...

Research Grants51

  1. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2007
    ..In summary, the proposed research will be sharply aimed at the discovery and very rapid development of new anticancer drugs for the NCI programs direct at improving human cancer treatments. ..
  2. Molecular Target Focused Discovery of Anticancer Drugs
    George R Pettit; Fiscal Year: 2010
    ....
  3. Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
    Lars Wagner; Fiscal Year: 2007
    ..We hypothesize this strategy will be well tolerated and allow for meaningful dose escalation through chemoprotection afforded by gene transfer into hematopoietic stem cells. [unreadable] [unreadable] [unreadable]..
  4. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  5. Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina
    Peter F Kador; Fiscal Year: 2010
    ..Moreover, these studies should help identify new drug targets for the treatment of these diabetic complications. ..
  6. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  7. Ovarian Cancer: Strategies for consolidation
    Paul Sabbatini; Fiscal Year: 2006
    ..Promising strategies will be moved to patients in primary remission (Specific Aim 1) with a current median time to treatment failure of 18-21 months...
  8. Genetic Polymorphisms Affecting Chemotherapy Disposition
    ALBERT LOCKHART; Fiscal Year: 2008
    ..abstract_text> ..
  9. Fatty Acid Synthase in Prostate Tumorigenesis
    BETH PFLUG; Fiscal Year: 2007
    ....
  10. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  11. Mechanisms of Action of Anti-Mitotic Drugs
    Mary Jordan; Fiscal Year: 2007
    ..The results will elucidate mechanisms and predict possible clinical efficacy of combination therapies directed at modulating mitotic microtubule regulatory proteins in combination with taxanes and Vinca alkaloids. ..
  12. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  13. Formulation Dependent Help Interactions with Chemothera*
    David Kroll; Fiscal Year: 2005
    ..These studies are designed in the interest of public health and the spirit that cancer patients should be steered away from harmful herbal products while being assured safe access to alternative formulations of the same herb. ..
  14. BOTANICAL/DRUG INTERACTIONS IN HIV: GLUCURONIDATION
    Philip Smith; Fiscal Year: 2004
    ..Piperine will also be examined in vitro for potential inhibition of oxidative metabolism of anti-HIV drugs such as the protease inhibitors. ..
  15. RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONS
    Dietmar Siemann; Fiscal Year: 2001
    ..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
  16. Colorectal Screening Capacity Building Conference
    David Alberts; Fiscal Year: 2003
    ..Continued capacity building and future collaboration will also be woven into this conference to serve as a stone to build upon in the future. ..
  17. 500MHz Console Upgrade
    Bruce Ganem; Fiscal Year: 2003
    ..T. McQuade will use NMR in designing new synthetic approaches to highly functionalized polymers; Prof. J. Meinwald will investigate the structures of biologically significant molecules involved in chemical communication. ..
  18. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  19. Generalized Varying-Coefficient Partially Linear Models
    Hua Liang; Fiscal Year: 2007
    ..The proposed research is expected to benefit semiparametric modeling as well as AIDS research. ..
  20. Anticancer Potential of Black Cohosh on Breast Cancer
    LINDA EINBOND; Fiscal Year: 2007
    ..This research project could identify new approaches to breast cancer prevention and therapy. ..
  21. Design of Gene Delivery System to Target Hepatocytes
    Mark Davis; Fiscal Year: 2008
    ..The long-term objective of our proposal is to design and engineer a generalized, synthetic system for ultimately delivering nucleic acid-based therapeutics to hepatocytes in humans. ..
  22. SYNTHESIS AND BIOSYNTHESIS IN THE SHIKIMATE PATHWAY
    Bruce Ganem; Fiscal Year: 2003
    ..R-Domain swapping experiments will establish whether feedback control elements in the P/T proteins are interchangeable, and whether different mechanisms are involved. ..
  23. MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARS
    Jonathan Berek; Fiscal Year: 2008
    ..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. [unreadable] [unreadable] [unreadable]..
  24. Nutrient Flavonoids and Lung Cancer Prevention
    Yong Lin; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. Chemoprevention of prostate cancer by resveratrol
    Tze Chen Hsieh; Fiscal Year: 2005
    ....
  26. Gene Polymorphism & Treatment-Symptoms in Lung Cancer
    Cielito Reyes Gibby; Fiscal Year: 2008
    ..abstract_text> ..
  27. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  28. Pharmacogenetic Determinants of Vinca Alkaloid Response
    Jamie Renbarger; Fiscal Year: 2009
    ..abstract_text> ..
  29. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  30. Multifunctional Antioxidants as Anti-Cataract Agents
    Peter Kador; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  31. ROLE OF INTESTINAL UGT IN DRUG DISPOSITION
    Philip Smith; Fiscal Year: 2005
    ..Translational studies to patients receiving these drugs will also be conducted to evaluate intestinal glucuronidation in humans and examine the hypothesis that local tissue specific UGTs may modulate intestinal toxicity in humans. ..
  32. Correlative Studies of erbB-2/HER2 and p53 in CALGB Pro.
    Daniel Hayes; Fiscal Year: 2005
    ....
  33. Mechanisms of Cancer Therapy Induced Pain
    Patrick Dougherty; Fiscal Year: 2006
    ..abstract_text> ..
  34. N-3 fatty acid & binding protein MRG on mammary tumor
    YUENIAN SHI; Fiscal Year: 2006
    ..These studies will help to identify MRG as mediator for differentiation for mammary gland and for interaction with n-3 PUPA on inhibition of mammary tumorigenesis. ..
  35. Intracellular Dorsal Horn Mechanisms of Pain Encoding
    Patrick Dougherty; Fiscal Year: 2004
    ....
  36. Analysis of AIDS Data by Using Semiparametrical Models
    Hua Liang; Fiscal Year: 2006
    ..The proposed research is expected to benefit studies of the immune system in HIV-infected patients (one of the main focuses of future AIDS research). ..
  37. SELECTIVE THERAPY OF NEUROBLASTOMA
    MARY DANKS; Fiscal Year: 2007
    ..Overall, these studies should provide alternative treatment modalities for high-risk neuroblastoma. ..
  38. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  39. TNF Blockade in Pancreatic Cancer Patients
    MIGUEL VILLALONA; Fiscal Year: 2004
    ..The observation of benefits in either quality of life or progression-free survival in patients undergoing TNF blockade would encourage evaluation of this novel strategy in properly powered randomized clinical trials. ..
  40. LIPOSOMAL BCL-2 ANTISENSE THERAPY FOR SOLID TUMORS
    Francisco Esteva; Fiscal Year: 2003
    ..Gabriel Lopez-Berestein (Department of Bioimmunotherapy). M. D. Anderson Cancer Center has the patients and resources necessary for Dr. Esteva to successfully complete this research project. ..
  41. Biomodulation of capecitabine by docetaxel in non-small*
    MIGUEL VILLALONA; Fiscal Year: 2005
    ..Confirmation of our working hypothesis may lead to a new treatment paradigm suitable for evaluation in the adjuvant setting. ..
  42. STUDIES OF TUBULIN-INTERACTIVE ANTICANCER DRUGS
    David Kingston; Fiscal Year: 2008
    ..Such compounds are expected to show good tubulin polymerization and cytotoxic properties, and may thus become synthetically accessible anticancer agents. ..
  43. NATIONAL WILMS TUMOR STUDY -5
    Daniel Green; Fiscal Year: 2003
    ..The survival of most children treated for WT allows the study of genetic and treatment factors associated with the etiology of the disease and/or the occurrence of complications of therapy. ..
  44. Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
    Bach Ardalan; Fiscal Year: 2008
    ..Aim 2: Determine if ATO administration down regulates the expression of thymidylate synthase in tumor and in PBMC in patients receiving ATO + 5-FU. [unreadable] [unreadable] [unreadable]..
  45. Shared UPLC-MS/MS for Absolute Quantitative Proteomics
    Philip Smith; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  46. Arsenite Effects on CD40 Signaling and B-Cell Apoptosis
    DONNA MUSCARELLA; Fiscal Year: 2008
    ..abstract_text> ..
  47. Non-Viral Vectors for Liver Gene Transfer
    Feng Liu; Fiscal Year: 2006
    ..The therapeutic effects on the metabolic disease on phenylketonuria (PKU) mice, will be examined after the PAH gene transfer using the approach in this proposal. ..
  48. Identification of Anti-Viral Compounds from Plants
    Shiyou Li; Fiscal Year: 2005
    ..abstract_text> ..
  49. CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
    Mark Ratain; Fiscal Year: 2002
    ..Since many of the studies include analysis of pharmacological specimens, the Committee utilizes three core laboratories--at the University of Chicago, the University of Maryland and the University of Tennessee. ..
  50. MOLECULAR DETERMINANTS OF MULTICELLULAR ORGANIZATION
    Douglas Hixson; Fiscal Year: 2003
    ..The proposed studies will provide new insights into the role of C-CAM in the interactions of normal hepatocytes and the consequences of the loss of C-CAM during liver carcinogenesis. ..
  51. CELLULAR ORIGINS OF LIVER CANCER
    Douglas Hixson; Fiscal Year: 2008
    ....